title: The dopamine D3/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset.
abstract: Previous work has shown that dopaminergic systems are involved in cognitive function in the common marmoset. The present study investigated the role of dopamine D3 receptors in cognitive performance in the marmoset. The effects of the putative dopamine D3 receptor agonist, 7-OH-DPAT, on performance of a same-day reversal visual object discrimination task were assessed using a miniature Wisconsin General Test Apparatus (WGTA). Within the same test session marmosets acquired a two-choice object discrimination initial task and a reversal task to criterion. 7-OH-DPAT (6-10 microg/kg) significantly impaired reversal task performance only, without affecting acquisition of the initial task. A higher dose of 25 microg/kg 7-OH-DPAT impaired initial task acquisition as well as reversal task acquisition, possibly as a consequence of a nonspecific influence on motor function. The dopamine D2 receptor antagonist (-)sulpiride (5-10 microg/kg) and the alpha2-receptor antagonist yohimbine (50 microg/kg) failed to attenuate the effects of 7-OH-DPAT (6 microg/kg) in this task. In contrast, the dopamine D2/D3 receptor antagonist raclopride (50 microg/kg) significantly attenuated the 7-OH-DPAT-induced impairment of reversal task performance. These results suggest that activation of dopamine D3 receptors produces a selective impairment of aspects of cognitive function in the marmoset.
authors.affiliation: Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, West Yorkshire, UK.
authors.forename: A G
authors.initials: AG
authors.lastname: Smith
authors.forename: J C
authors.initials: JC
authors.lastname: Neill
authors.forename: B
authors.initials: B
authors.lastname: Costall
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002144:Callithrix; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D004193:Discrimination Learning / Q000187:drug effects / Q000502:physiology; D018491:Dopamine Agonists / Q000633:toxicity*; D018492:Dopamine Antagonists / Q000494:pharmacology; D005260:Female; D008297:Male; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000819:agonists; D050637:Receptors, Dopamine D3; D012457:Salicylamides / Q000494:pharmacology; D013469:Sulpiride / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000633:toxicity*; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D012457:Salicylamides; D013764:Tetrahydronaphthalenes; D015016:Yohimbine; D020891:Raclopride; D013469:Sulpiride; C031349:7-hydroxy-2-N,N-dipropylaminotetralin